Summary of National Surveillance Data on Vaccine Preventable Diseases in Australia, 2019–2022
DOI:
https://doi.org/10.33321/cdi.2026.50.040Keywords:
national surveillance data, vaccine preventable diseases, Australia, immunisation, notification, hospitalisation, mortalityAbstract
This summary report on vaccine preventable diseases in Australia is the latest in a series of multi-year surveillance reports that bring together the three most important national sources of routinely-collected data on VPDs (notifications, hospitalisations and deaths) and serve as a resource to support surveillance and control of VPDs in Australia. This report focuses on the four-year period 1 January 2019 to 31 December 2022 with longer term trends also presented. Two VPDs are included for the first time: coronavirus disease 2019 (COVID-19) and Japanese encephalitis virus (JEV) infection.
Downloads
References
Brotherton J, McIntyre P, Puech M, Wang H, Gidding H, Hull B et al. Vaccine preventable diseases and vaccination coverage in Australia 2001 to 2002. Commun Dis Intell Q Rep. 2004;28(Suppl 2):vii–S116. doi: https://doi.org/10.33321/cdi.2004.28.65.
Brotherton J, Wang H, Schaffer A, Quinn H, Menzies R, Hull B et al. Vaccine preventable diseases and vaccination coverage in Australia, 2003 to 2005. Commun Dis Intell Q Rep. 2007;31(Suppl):S1–152. doi: https://doi.org/10.33321/cdi.2007.31.25.
Chiu C, Dey A, Wang H, Menzies R, Deeks S, Mahajan D et al. Vaccine preventable diseases in Australia, 2005 to 2007. Commun Dis Intell Q Rep. 2010;34(Supp):S1–167. doi: https://doi.org/10.33321/cdi.2010.34.48.
Dey A, Knox S, Wang H, Beard FH, McIntyre PB. Summary of National Surveillance Data on Vaccine Preventable Diseases in Australia, 2008–2011. Commun Dis Intell Q Rep. 2016;40(Suppl):S1–70. doi: https://doi.org/10.33321/cdi.2016.40.11.
Dey A, Wang H, Beard F, Macartney K, McIntyre P. Summary of national surveillance data on vaccine preventable diseases in Australia, 2012–2015. Commun Dis Intell (2018). 2019;43. doi: https://doi.org/10.33321/cdi.2019.43.58.
Patel C, Dey A, Wang H, McIntyre P, Macartney K, Beard F. Summary of National Surveillance Data on Vaccine Preventable Diseases in Australia, 2016–2018 Final Report. Commun Dis Intell (2018). 2022;46. doi: https://doi.org/10.33321/cdi.2022.46.28.
Ioannides S, Beard F, Larter N, Clark K, Wang H, Hendry A et al. Vaccine Preventable Diseases and Vaccination Coverage in Aboriginal and Torres Strait Islander People, Australia, 2011–2015. Commun Dis Intell (2018). 2019;43. doi: https://doi.org/10.33321/cdi.2019.43.36.
Jackson J, Sonneveld N, Rashid H, Karpish L, Wallace S, Whop L et al. Vaccine Preventable Diseases and Vaccination Coverage in Aboriginal and Torres Strait Islander People, Australia, 2016–2019. Commun Dis Intell (2018). 2023;47. doi: https://doi.org/10.33321/cdi.2023.47.32.
Naidu L, Chiu C, Habig A, Lowbridge C, Jayasinghe S, Wang H et al. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia 2006–2010. Commun Dis Intell Q Rep. 2013;37(Suppl):S1–95. doi: https://doi.org/10.33321/cdi.2013.37.64.
Morris ESG, Dey A, Vette K, Rashid H, Wood N, Beard F. Australian vaccine preventable disease epidemiological review series: tetanus 2003–2019. Commun Dis Intell (2018). 2023;47. doi: https://doi.org/10.33321/cdi.2023.47.61.
Sonneveld N, Jackson J, Dey A, Lambert SB, Clark KK, Cowie BC et al. Australian vaccine preventable disease epidemiological review series: Hepatitis B, 2000–2019. Commun Dis Intell (2018). 2024;48. doi: https://doi.org/10.33321/cdi.2024.48.44.
Winkler NE, Dey A, Quinn HE, Pourmarzi D, Lambert S, McIntyre P et al. Australian vaccine preventable disease epidemiological review series: measles, 2012–2019. Commun Dis Intell (2018). 2022;46. doi: https://doi.org/10.33321/cdi.2022.46.38.
Winkler NE, Dey A, Quinn HE, Pourmarzi D, Lambert S, McIntyre P et al. Australian vaccine preventable disease epidemiological review series: diphtheria 1999–2019. Commun Dis Intell (2018). 2022;46. doi: https://doi.org/10.33321/cdi.2022.46.42.
Australian Institute of Health and Welfare (AIHW). National Cervical Screening Program monitoring report 2024. Canberra: Australian Government, AIHW; 3 December 2024. Available from: https://www.aihw.gov.au/reports/cancer-screening/ncsp-monitoring-2024/summary.
Bright A, Denholm J, Coulter C, Waring J, Stapledon R. Tuberculosis notifications in Australia, 2015–2018. Commun Dis Intell (2018). 2020;44. doi: https://doi.org/10.33321/cdi.2020.44.88.
Australian Government Department of Health, Disability and Ageing. CDNA surveillance case definitions. [Webpage.] Canberra: Australian Government Department of Health, Disability and Ageing; 29 May 2022. [Accessed on 16 October 2024.] Available from: https://www.health.gov.au/resources/collections/cdna-surveillance-case-definitions#a.
Australian Bureau of Statistics (ABS). National, state and territory population. Reference period: December 2022. [Webpage.] Canberra: ABS; 16 June 2023. [Accessed on 4 October 2024.] Available from: https://www.abs.gov.au/statistics/people/population/national-state-and-territory-population/dec-2022.
ABS. Estimates and Projections, Aboriginal and Torres Strait Islander Australians. Reference period: 2006 to 2031. [Webpage.] Canberra: ABS; 11 July 2019. [Accessed on 4 October 2024.] Available from: https://www.abs.gov.au/statistics/people/aboriginal-and-torres-strait-islander-peoples/estimates-and-projections-aboriginal-and-torres-strait-islander-australians/2006-2031.
AIHW. Principles on the use of direct age-standardisation in administrative data collections: for measuring the gap between Indigenous and non-Indigenous Australians. Canberra: Australian Government, AIHW; 7 October 2011. Available from: https://www.aihw.gov.au/reports/indigenous-australians/principles-on-the-use-of-direct-age-standardisatio.
Michel JL, Cheng D, Jackson TJ. Comparing the coding of complications in Queensland and Victorian admitted patient data. Aust Health Rev. 2011;35(3):245–52. doi: https://doi.org/10.1071/AH09783.
AIHW. Variation in hospital admission policies and practices: Australian hospital statistics. Canberra: Australian Government, AIHW; 27 November 2017. Available from: https://www.aihw.gov.au/reports/hospitals/variation-hospital-admission-policies-practices/formats.
Perlman S, Denison MR. Chapter 17 – Coronavirus Vaccines. In Orenstein W, Offit P, Edwards KM, Plotkin S, eds. Plotkin's Vaccines. (Eighth edition). Philadelphia: Elsevier, 2023;248–57.e9. doi: https://doi.org/10.1016/B978-0-323-79058-1.00017-7.
Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141–54. doi: https://doi.org/10.1038/s41579-020-00459-7.
Bhatia KS, Sritharan HP, Chia J, Coifani J, Nour D, Chui K et al. Cardiac complications in patients hospitalised with COVID-19 in Australia. Heart Lung Circ. 2021;30(12):1834–40. doi: https://doi.org/10.1016/j.hlc.2021.08.001.
Cini C, Neto AS, Burrell A, Udy A, SPRINT-SARI Australia investigators. Inter-hospital transfer and clinical outcomes for people with COVID-19 admitted to intensive care units in Australia: an observational cohort study. Med J Aust. 2023;218(10):474–81. doi: https://doi.org/10.5694/mja2.51917.
Wurzel D, McMinn A, Hoq M, Blyth CC, Burgner D, Tosif S et al. Prospective characterisation of SARS-CoV-2 infections among children presenting to tertiary paediatric hospitals across Australia in 2020: a national cohort study. BMJ Open. 2021;11(11):e054510. doi: https://doi.org/10.1136/bmjopen-2021-054510.
Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934–43. doi: https://doi.org/10.1001/jamainternmed.2020.0994.
Rasmussen SA, Jamieson DJ. COVID-19 and Pregnancy. Infect Dis Clin North Am. 2022;36(2):423–33. doi: https://doi.org/10.1016/j.idc.2022.01.002.
Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22(4):e102–7. doi: https://doi.org/10.1016/S1473-3099(21)00703-9.
Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265–9. doi: https://doi.org/10.1038/s41586-020-2008-3.
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–3. doi: https://doi.org/10.1038/s41586-020-2012-7.
World Health Organization. (WHO). WHO Statement regarding cluster of pneumonia cases in Wuhan, China. [Online statement.] Geneva: WHO; 9 January 2020. [Accessed on 14 November 2024.] Available from: https://www.who.int/china/news/detail/09-01-2020-who-statement-regarding-cluster-of-pneumonia-cases-in-wuhan-china.
WHO. WHO Director-General's opening remarks at the media briefing on COVID-19 – 11 March 2020. [Online statement.] Geneva: WHO; 11 March 2020. [Accessed on 14 November 2024.] Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.
Schumacher AE, Kyu HH, Aali A, Abbafati C, Abbas J, Abbasgholizadeh R et al. Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):1989–2056. doi: https://doi.org/10.1016/S0140-6736(24)00476-8.
Milazzo A, Giles L, Parent N, McCarthy S, Laurence C. The impact of non-pharmaceutical interventions on COVID-19 cases in South Australia and Victoria. Aust N Z J Public Health. 2022;46(4):482–7. doi: https://doi.org/10.1111/1753-6405.13249.
Shearer FM, McCaw JM, Ryan GE, Hao T, Tierney NJ, Lydeamore M et al. Estimating the impact of test–trace–isolate–quarantine systems on SARS-CoV-2 transmission in Australia. Epidemics. 2024;47:100764. doi: https://doi.org/10.1016/j.epidem.2024.100764.
Hall RN, Jones A, Crean E, Marriott V, Pingault N, Marmor A et al. Public health interventions successfully mitigated multiple incursions of SARS-CoV-2 Delta variant in the Australian Capital Territory. Epidemiol Infect. 2023;151:e30. doi: https://doi.org/10.1017/S0950268823000201.
Bush M, Hutchinson A, Bouchoucha SL, Bennett CM. Mapping Australia's COVID-19 quarantine cohort journeys. Infect Dis Health. 2024;29(4):233–42. doi: https://doi.org/10.1016/j.idh.2024.07.001.
Australian Government Department of the Prime Minister and Cabinet. COVID-19 Response Inquiry Report. Canberra: Australian Government Department of the Prime Minister and Cabinet; 29 October 2024. Available from: https://www.pmc.gov.au/resources/covid-19-response-inquiry-report.
Koirala A, Gidding HF, Vette K, Macartney K, PAEDS Serosurvey Group. The seroprevalence of SARS-CoV-2-specific antibodies in children, Australia, November 2020 – March 2021. Med J Aust. 2022;217(1):43–5. doi: https://doi.org/10.5694/mja2.51542.
Vette KM, Machalek DA, Gidding HF, Nicholson S, O’Sullivan MVN, Carlin JB et al. Seroprevalence of severe acute respiratory syndrome coronavirus 2-specific antibodies in Australia after the first epidemic wave in 2020: a national survey. Open Forum Infect Dis. 2022;9(3):ofac002. doi: https://doi.org/10.1093/ofid/ofac002.
Australian Government Operation COVID Shield. COVID-19 Vaccine Roll-out: 03 January 2022. [Webpage.] Canberra: Australian Government Department of Health, Disability and Ageing; 3 January 2022. [Accessed on 14 November 2024.] Available from: https://www.health.gov.au/sites/default/files/documents/2022/01/covid-19-vaccine-rollout-update-3-january-2022.pdf.
Australian Bureau of Statistics. Deaths, Australia. Reference period: 2022. [Webpage.] Canberra: ABS; 27 September 2023. [Accessed on 5 December 2024.] Available from: https://www.abs.gov.au/statistics/people/population/deaths-australia/2022.
ABS. COVID-19 first infectious disease in top 5 causes of death since 1970. [Media release.] Canberra: ABS; 27 September 2023. [Accessed on 5 October 2024.] Available from: https://www.abs.gov.au/media-centre/media-releases/covid-19-first-infectious-disease-top-5-causes-death-1970.
Liu B, Stepien S, Dobbins T, Gidding H, Henry D, Korda R et al. Effectiveness of COVID-19 vaccination against COVID-19 specific and all-cause mortality in older Australians: a population based study. Lancet Reg Health West Pac. 2023;40:100928. doi: https://doi.org/10.1016/j.lanwpc.2023.100928.
Liu B, Stepien S, Sharma K, Macartney K. Effectiveness of bivalent COVID-19 boosters against COVID-19 mortality in people aged 65 years and older, Australia, November 2022 to May 2023. Euro Surveill. 2023;28(47):2300603. doi: https://doi.org/10.2807/1560-7917.ES.2023.28.47.2300603.
Follent D, Paulson C, Orcher P, O’Neill B, Lee D, Briscoe K et al. The indirect impacts of COVID-19 on Aboriginal communities across New South Wales. Med J Aust. 2021;214(5):199–200.e1. doi: https://doi.org/10.5694/mja2.50948.
Yashadhana A, Pollard-Wharton N, Zwi AB, Biles B. Indigenous Australians at increased risk of COVID-19 due to existing health and socioeconomic inequities. Lancet Reg Health West Pac. 2020;1:100007. doi: https://doi.org/10.1016/j.lanwpc.2020.100007.
Griffee MJ, Thomson DA, Fanning J, Rosenberger D, Barnett A, White NM et al. Race and ethnicity in the COVID-19 Critical Care Consortium: demographics, treatments, and outcomes, an international observational registry study. Int J Equity Health. 2023;22(1):260. doi: https://doi.org/10.1186/s12939-023-02051-w.
Acosta AM, Wharton M. Chapter 21 – Diphtheria Toxoid. In Orenstein W, Offit P, Edwards KM, Plotkin S, eds. Plotkin's Vaccines. (Eighth edition). Philadelphia: Elsevier, 2023;298–310.e8. doi: https://doi.org/10.1016/B978-0-323-79058-1.00021-9.
Truelove SA, Keegan LT, Moss WJ, Chaisson LH, Macher R, Azman AS et al. Clinical and epidemiological aspects of diphtheria: a systematic review and pooled analysis. Clin Infect Dis. 2020;71(1):89–97. doi: https://doi.org/10.1093/cid/ciz808.
Slinko VG, Guglielmino CJ, Uren AM, Smith JKG, Neucom D, Smoll NR et al. Several confirmed and probable zoonotic cases of toxigenic Corynebacterium ulcerans, Queensland, Australia. Commun Dis Intell (2018). 2023;47. doi: https://doi.org/10.33321/cdi.2023.47.53.
Wagner KS, White JM, Lucenko I, Mercer D, Crowcroft NS, Neal S et al. Diphtheria in the postepidemic period, Europe, 2000–2009. Emerg Infect Dis. 2012;18(2):217–25. doi: https://doi.org/10.3201/eid1802.110987.
United States Centers for Disease Control and Prevention (US CDC). Diphtheria. [Webpage.] Atlanta: United States Government Department of Health and Human Services, US CDC; 2022. [Accessed on 10 October 2024.] Available from: https://www.cdc.gov/diphtheria/index.html.
Hempenstall A, Short J, Marquardt T, Fisher V, Johnson J. Clinician alert: toxigenic diphtheria cases across North Queensland are on the rise. Med J Aust. 2023;218(5):238. doi: https://doi.org/10.5694/mja2.51858.
Parliament of Australia, Senate Select Committee on COVID-19. Appendix 2: Timeline of key decisions and milestones. [Webpage.] Canberra: Parliament of Australia; 2022. [Accessed on 9 September 2024.]
Australian Government Department of Health, Disability and Ageing; Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. [Online resource.] Canberra: Australian Government Department of Health, Disability and Ageing; 2022. Available from: immunisationhandbook.health.gov.au.
Hull B, Hendry A, Dey A, Brotherton J, Macartney K, Beard F. Annual Immunisation Coverage Report 2022. Commun Dis Intell (2018). 2025;49. doi: https://doi.org/10.33321/cdi.2025.49.023.
Hasselhorn HM, Nubling M, Tiller FW, Hofmann F. Factors influencing immunity against diphtheria in adults. Vaccine. 1998;16(1):70–5. doi: https://doi.org/10.1016/s0264-410x(97)00148-5.
Liu D, Cheng X, Wei S, Yuan L, Chen C, Yao K. Decline of serologic immunity to diphtheria, tetanus and pertussis with age suggested a full life vaccination in mainland China. Hum Vaccin Immunother. 2021;17(6):1757–62. doi: https://doi.org/10.1080/21645515.2020.1840253.
Maple PA, Jones CS, Wall EC, Vyseb A, Edmunds WJ, Andrews NJ et al. Immunity to diphtheria and tetanus in England and Wales. Vaccine. 2000;19(2–3):167–73. doi: https://doi.org/10.1016/s0264-410x(00)00184-5.
McQuillan GM, Kruszon-Moran D, Deforest A, Chu SY, Wharton M. Serologic immunity to diphtheria and tetanus in the United States. Ann Intern Med. 2002;136(9):660–6. doi: https://doi.org/10.7326/0003-4819-136-9-200205070-00008.
Hendry AJ, Quinn HE, Macartney K, Beard FH. Tetanus, pertussis, and diphtheria vaccination coverage in older adults, Australia, 2023: analysis of Australian Immunisation Register data. Med J Aust. 2024;221(4):224–5. doi: https://doi.org/10.5694/mja2.52389.
Howard AJ, Dunkin KT, Millar GW. Nasopharyngeal carriage and antibiotic resistance of Haemophilus influenzae in healthy children. Epidemiol Infect. 1988;100(2):193–203. doi: https://doi.org/10.1017/s0950268800067327.
McVernon J, Howard AJ, Slack MP, Ramsay ME. Long-term impact of vaccination on Haemophilus influenzae type b (Hib) carriage in the United Kingdom. Epidemiol Infect. 2004;132(4):765–7. doi: https://doi.org/10.1017/s0950268804002122.
Jacups SP, Morris PS, Leach AJ. Haemophilus influenzae type b carriage in Indigenous children and children attending childcare centers in the Northern Territory, Australia, spanning pre- and post-vaccine eras. Vaccine. 2011;29(16):3083–8. doi: https://doi.org/10.1016/j.vaccine.2010.09.030.
Gilbert GL, Johnson PD, Clements DA. Clinical manifestations and outcome of Haemophilus influenzae type b disease. J Paediatr Child Health. 1995;31(2):99–104. doi: https://doi.org/10.1111/j.1440-1754.1995.tb00755.x.
Wood N, Menzies R, McIntyre P. Epiglottitis in Sydney before and after the introduction of vaccination against Haemophilus influenzae type b disease. Intern Med J. 2005;35(9):530–5. doi: https://doi.org/10.1111/j.1445-5994.2005.00909.x.
Fitzwater SP, Kahn GD, Chandran A, Santosham M. Chapter 25 – Haemophilus influenzae Type b Vaccines. In Orenstein W, Offit P, Edwards KM, Plotkin S, eds. Plotkin's Vaccines. (Eighth edition). Philadelphia: Elsevier, 2023;348–64.e9. doi: https://doi.org/10.1016/B978-0-323-79058-1.00025-6.
Menzies RI, Bremner KM, Wang H, Beard FH, McIntyre PB. Long-term trends in invasive Haemophilus influenzae type B disease among Indigenous Australian children following use of PRP-OMP and PRP-T vaccines. Pediatr Infect Dis J. 2015;34(6):621–6. doi: https://doi.org/10.1097/INF.0000000000000681.
Wang H, Deeks S, Glasswell A, McIntyre P. Trends in invasive Haemophilus influenzae type B disease in Australia, 1995–2005. Commun Dis Intell Q Rep. 2008;32(3):316–25. doi: https://doi.org/10.33321/cdi.2008.32.32.
Maguire JE, Beard F, Méder K, Dey A, Macartney K, McIntyre P. Australian vaccine preventable disease epidemiological review series: invasive Haemophilus influenzae type b disease, 2000–2017. Commun Dis Intell (2018). 2020;44. doi: https://doi.org/10.33321/cdi.2020.44.11.
McIntyre PB, O'Brien KL, Greenwood B, van de Beek D. Effect of vaccines on bacterial meningitis worldwide. Lancet. 2012;380(9854):1703–11. doi: https://doi.org/10.1016/S0140-6736(12)61187-8.
Wahl B, O'Brien KL, Greenbaum A, Majumder A, Liu L, Chu Y et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15. Lancet Glob Health. 2018;6(7):e744–57. doi: https://doi.org/10.1016/S2214-109X(18)30247-X.
Shaw D, Abad R, Amin-Chowdhury Z, Bautista A, Bennett D, Broughton K et al. Trends in invasive bacterial diseases during the first 2 years of the COVID-19 pandemic: analyses of prospective surveillance data from 30 countries and territories in the IRIS Consortium. Lancet Digit Health. 2023;5(9):e582–93. doi: https://doi.org/10.1016/S2589-7500(23)00108-5.
National Centre for Immunisation Research and Surveillance (NCIRS). Significant events in Haemophilus influenzae type b vaccination practice in Australia. Sydney: Sydney Children’s Hospitals Network; February 2024. [Accessed on 6 March 2024.]
Walsh NM, Soeters HM, Nelson NP, Khudyakov Y, Weng MK. Chapter 26 – Hepatitis A Vaccines. In Orenstein W, Offit P, Edwards KM, Plotkin S, eds. Plotkin's Vaccines. (Eighth edition). Philadelphia: Elsevier, 2023;365–88.e15. doi: https://doi.org/10.1016/B978-0-323-79058-1.00026-8.
Lednar WM, Lemon SM, Kirkpatrick JW, Redfield RR, Fields ML, Kelley PW. Frequency of illness associated with epidemic hepatitis A virus infections in adults. Am J Epidemiol. 1985;122(2):226–33. doi: https://doi.org/10.1093/oxfordjournals.aje.a114093.
Ali H, Regan DG, Guy RJ, Robertson P, Watchirs-Smith L, McNulty AM et al. Increasing hepatitis A immunity in men who have sex with men in Sydney, 1996–2012. Vaccine. 2015;33(38):4745–7. doi: https://doi.org/10.1016/j.vaccine.2015.01.090.
Heywood AE, Newall AT, Gao Z, Wood JG, Breschkin A, Nicholson S et al. Changes in seroprevalence to hepatitis A in Victoria, Australia: a comparison of three time points. Vaccine. 2012;30(42):6020–6. doi: https://doi.org/10.1016/j.vaccine.2012.07.058.
Jayasundara D, Hui BB, Regan DG, Heywood AE, MacIntyre CR, Wood JG. Quantifying the population effects of vaccination and migration on hepatitis A seroepidemiology in Australia. Vaccine. 2017;35(39):5228–34. doi: https://doi.org/10.1016/j.vaccine.2017.08.022.
Burrell S, Vodstrcil LA, Fairley CK, Kilner A, Cradshaw CS, Chen MY et al. Hepatitis A vaccine uptake among men who have sex with men from a time-limited vaccination programme in Melbourne in 2018. Sex Transm Infect. 2020;96(2):110–4. doi: https://doi.org/10.1136/sextrans-2019-054132.
NCIRS. Significant events in hepatitis A vaccination practices in Australia. Sydney: Sydney Children’s Hospitals Network; November 2025. [Accessed on 2 July 2026.]
O'Neill C, Franklin N, Edwards A, Martin T, O’Keefe J, Jackson K et al. Hepatitis A outbreak in Australia linked to imported Medjool dates, June–September 2021. Commun Dis Intell (2018). 2022;46. doi: https://doi.org/10.33321/cdi.2022.46.68.
Van Damme P, Ward JW, Shouval D, Zanetti A. Chapter 25 – Hepatitis B Vaccines. In Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. Plotkin's Vaccines. (Seventh edition.) Amsterdam: Elsevier, 2018;342–74.e17. doi: https://doi.org/10.1016/B978-0-323-35761-6.00025-0.
McMahon BJ, Alward WL, Hall DB, Heyward WL, Bender TR, Francis DP et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis. 1985;151(4):599–603. doi: https://doi.org/10.1093/infdis/151.4.599.
Edmunds WJ, Medley GF, Nokes DJ, Hall AJ, Whittle HC. The influence of age on the development of the hepatitis B carrier state. Proc Biol Sci. 1993;253(1337):197–201. doi: https://doi.org/10.1098/rspb.1993.0102.
He WQ, Duong MC, Gidding H, MacLachlan J, Wood J, Kaldor JM et al. Trends in chronic hepatitis B prevalence in Australian women by country of birth, 2000 to 2016. J Viral Hepat. 2020;27(1):74–80. doi: https://doi.org/10.1111/jvh.13202.
Graham S, MacLachlan JH, Gunaratnam P, Cowie BC. Chronic hepatitis B prevalence in Australian Aboriginal and Torres Strait Islander people before and after implementing a universal vaccination program: a systematic review and meta-analysis. Sex Health. 2019;16(3):201–11. doi: https://doi.org/10.1071/SH18150.
Dyda A, McGregor S, Binks P, Davies J, Tong SYC, Krause V et al. Hepatitis B prevalence in women giving birth in the Northern Territory, Australia, 2005–2015. Commun Dis Intell (2018). 2022;46. doi: https://doi.org/10.33321/cdi.2022.46.62.
Shah SHBU, Alavi M, Hajarizadeh B, Matthews GV, Martinello M, Danta M et al. Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales. JHEP Rep. 2022;4(10):100552. doi: https://doi.org/10.1016/j.jhepr.2022.100552.
Howell J, Pedrana A, Cowie BC, Doyle J, Getahun A, Ward J et al. Aiming for the elimination of viral hepatitis in Australia, New Zealand, and the Pacific Islands and Territories: where are we now and barriers to meeting World Health Organization targets by 2030. J Gastroenterol Hepatol. 2019;34(1):40–8. doi: https://doi.org/10.1111/jgh.14457.
McCulloch K, Romero N, MacLachlan J, Allard N, Cowie B. Modeling progress toward elimination of hepatitis B in Australia. Hepatology. 2020;71(4):1170–81. doi: https://doi.org/10.1002/hep.30899.
McCulloch K, Romero N, Allard N, MacLachlan JH, Cowie BC. Modelling jurisdictional disparities in the cascade of care for chronic hepatitis B in Australia: impact of treatment uptake on mortality. Aust N Z J Public Health. 2023;47(1):100011. doi: https://doi.org/10.1016/j.anzjph.2022.100011.
Deng L, Reekie J, Hayen A, Kong M, Kaldor JM, Ward J et al. Comparison of recording of hepatitis B infection in the NSW Perinatal Data Collection with linked hepatitis B notifications. Public Health Res Pract. 2017;27(5):e2751745. doi: https://doi.org/10.17061/phrp2751745.
Shen EX, Lambert SB, Malo JA, Bennett S, Sheridan SL, Vasant BR et al. Perinatal immunoprophylaxis in babies born to hepatitis B virus-positive mothers in Queensland Australia: a data linkage study. Vaccine. 2019;37(22):2884–8. doi: https://doi.org/10.1016/j.vaccine.2019.04.052.
Deng HM-A, Romero N, Allard N, Rowe S, Yussf N, Cowie B. Uptake of perinatal immunoprophylaxis for infants born to women with a record of hepatitis B in Victoria (2009–2017). Vaccine. 2023;41(10):1726–34. doi: https://doi.org/10.1016/j.vaccine.2023.01.045.
Sullivan RP, Davies J, Binks P, McKinnon M, Dhurrkay RG, Hosking K et al. Preventing early childhood transmission of hepatitis B in remote Aboriginal communities in northern Australia. Int J Equity Health. 2022;21(1):186. doi: https://doi.org/10.1186/s12939-022-01808-z.
MacLachlan JH, Romero N, Higgins N, Coutts R, Chan R, Stephens N et al. Epidemiology of chronic hepatitis B and C in Victoria, Australia: insights and impacts from enhanced surveillance. Aust N Z J Public Health. 2020;44(1):59–64. doi: https://doi.org/10.1111/1753-6405.12934.
Jacob R, Prince DS, Pipicella JL, Nguyen A, Bagatella M, Alvaro F et al. Routine screening of emergency admissions at risk of chronic hepatitis (SEARCH) identifies and links hepatitis B cases to care. Liver Int. 2023;43(1):60–8. doi: https://doi.org/10.1111/liv.15414.
Xiao Y, Hellard ME, Thompson AJ, Seaman C, Howell J, Scott N. The cost-effectiveness of universal hepatitis B screening for reaching WHO diagnosis targets in Australia by 2030. Med J Aust. 2023;218(4):168–73. doi: https://doi.org/10.5694/mja2.51825.
Allard NL, MacLachlan JH, Tran L, Yussf N, Cowie BC. Time for universal hepatitis B screening for Australian adults. Med J Aust. 2021;215(3):103–5.e1. doi: https://doi.org/10.5694/mja2.51114.
Sievert K, Liddle R, Tan A, Arachchi N, Valaydon Z, Allard N. Promoting hospital and primary care collaboration for timely and effective care for chronic hepatitis B in western Melbourne. Aust Health Rev. 2020;44(4):521–6. doi: https://doi.org/10.1071/AH19135.
Hosking K, De Santis T, Vintour-Cesar E, Wilson PM, Bunn L, Gurriwiwi GG et al. “Putting the power back into community”: a mixed methods evaluation of a chronic hepatitis B training course for the Aboriginal health workforce of Australia’s Northern Territory. PLoS One. 2024;19(1):e0288577. doi: https://doi.org/10.1371/journal.pone.0288577.
Hla TK, Bukulatjpi SM, Binks P, Gurriwiwi GG, Dhurrkay RG, Davies J et al. A “one stop liver shop” approach improves the cascade-of-care for Aboriginal and Torres Strait Islander Australians living with chronic hepatitis B in the Northern Territory of Australia: results of a novel care delivery model. Int J Equity Health. 2020;19(1):64. doi: https://doi.org/10.1186/s12939-020-01180-w.
Taye BW, Valery PC, Liddle B, Woodward AJ, Sackey D, Williams S et al. Fitting health care to people: understanding and adapting to the epidemiology and health literacy of people affected by viral hepatitis from culturally and linguistically diverse migrant backgrounds. J Immigr Minor Health. 2022;24(5):1196–205. doi: https://doi.org/10.1007/s10903-021-01305-5.
Hosking K, Binks P, De Santis T, Wilson PM, Gurruwiwi GG, Bukulatjpi SM et al. Evaluating a novel model of hepatitis B care, Hep B PAST, in the Northern Territory of Australia: results from a prospective, population-based study. Lancet Reg Health West Pac. 2024;48:101116. doi: https://doi.org/10.1016/j.lanwpc.2024.101116.
Xiao Y, Wallace J, Ahad M, van Gemert C, Thompson AJ, Doyle J et al. Assessing the feasibility, acceptability and impacts of an education program on hepatitis B testing uptake among ethnic Chinese in Australia: results of a randomised controlled pilot study. BMC Public Health. 2021;21(1):1861. doi: https://doi.org/10.1186/s12889-021-11916-0.
Patel MM, Grohskopf LA, Sambhara S, Belser JA, Katz JM, Fry AM. Chapter 33 – Inactivated and Recombinant Influenza Vaccines. In Orenstein W, Offit P, Edwards KM, Plotkin S, eds. Plotkin's Vaccines. (Eighth edition). Philadelphia: Elsevier, 2023;514–51.e31. doi: https://doi.org/10.1016/B978-0-323-79058-1.00033-5.
Rothberg MB, Haessler SD, Brown RB. Complications of viral influenza. Am J Med. 2008;121(4):258–64. doi: https://doi.org/10.1016/j.amjmed.2007.10.040.
Warren-Gash C, Blackburn R, Whitaker H, McMenamin J, Hayward AC. Laboratory-confirmed respiratory infections as triggers for acute myocardial infarction and stroke: a self-controlled case series analysis of national linked datasets from Scotland. Eur Respir J. 2018;51(3):1701794. doi: https://doi.org/10.1183/13993003.01794-2017.
Norman DA, Cheng AC, Macartney KK, Moore HC, Danchin M, Seale H et al. Influenza hospitalizations in Australian children 2010–2019: the impact of medical comorbidities on outcomes, vaccine coverage, and effectiveness. Influenza Other Respir Viruses. 2022;16(2):316–27. doi: https://doi.org/10.1111/irv.12939.
Australian Government Department of Health, Disability and Ageing; National Notifiable Disease Surveillance System. National Communicable Disease Surveillance Dashboard. [Online resource.] Canberra: Australian Government Department of Health, Disability and Ageing; 2024. [Accessed on 12 September 2024.] Available from: https://nindss.health.gov.au/pbi-dashboard/.
Adegbija O, Walker J, Smoll N, Khan A, Graham J, Khandaker G. Notifiable diseases after implementation of COVID-19 public health prevention measures in Central Queensland, Australia. Commun Dis Intell (2018). 2021;45. doi: https://doi.org/10.33321/cdi.2021.45.11.
Bhatt P, Strachan J, Easton M, Franklin L, Drewett G. Effect of COVID-19 restrictions and border closures on vaccine preventable diseases in Victoria, Australia, 2020–2021. Commun Dis Intell (2018). 2022;46. doi: https://doi.org/10.33321/cdi.2022.46.29.
O'Neill GK, Taylor J, Kok J, Dwyer DE, Dilcher M, Hua H et al. Circulation of influenza and other respiratory viruses during the COVID-19 pandemic in Australia and New Zealand, 2020–2021. Western Pac Surveill Response J. 2023;14:1–9. doi: https://doi.org/10.5365/wpsar.2023.14.3.948.
Dhanasekaran V, Sullivan S, Edwards KM, Xie R, Khorov A, Valkenburg SA et al. Human seasonal influenza under COVID-19 and the potential consequences of influenza lineage elimination. Nat Commun. 2022;13(1):1721. doi: https://doi.org/10.1038/s41467-022-29402-5.
WHO. Recommended composition of influenza virus vaccines for use in the 2024 southern hemisphere influenza season. [Meeting report.] Geneva: WHO; 29 September 2023. [Accessed on 16 October 2024.] Available from: https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2024-southern-hemisphere-influenza-season.
Sheppeard V, Gilmour R, Tobin S. Record number of influenza tests in 2019, not a "mutant flu crisis". Med J Aust. 2019;211(7):333e1. doi: https://doi.org/10.5694/mja2.50321.
Therapeutic Goods Administration (TGA). First combination COVID-19 and influenza self-tests approved for Australia. [Media release.] Canberra: Australian Government Department of Health, Disability and Ageing; 7 September 2022. [Accessed on 12 September 2024.] Available from: https://www.tga.gov.au/news/media-releases/first-combination-covid-19-and-influenza-self-tests-approved-australia.
Beard F, Molnar E, Jackson J, Vette K, Clark K, Dey A et al. Evaluation of Indigenous status completeness in vaccine preventable disease notification data in the NNDSS. Commun Dis Intell (2018). 2025;49. doi:https://doi.org/10.33321/cdi.2025.49.029.
Hull B, Hendry A, Dey A, Brotherton J, Macartney K, Beard F. Annual Immunisation Coverage Report 2020. Commun Dis Intell (2018). 2022;46. doi: https://doi.org/10.33321/cdi.2022.46.60.
Li-Kim-Moy J, Yin JK, Blyth CC, Kesson A, Booy R, Cheng AC et al. Influenza hospitalizations in Australian children. Epidemiol Infect. 2017;145(7):1451–60. doi: https://doi.org/10.1017/S0950268816003381.
McRae JE, McHugh L, King C, Beard FH, Blyth CC, Danchin MH et al. Influenza and pertussis vaccine coverage in pregnancy in Australia, 2016–2021. Med J Aust. 2023;218(11):528–41. doi: https://doi.org/10.5694/mja2.51989.
McNamara LA, Pollard AJ, Harrison LH. Chapter 39 – Meningococcal Capsular Group A, C, W, and Y Conjugate Vaccines. In Orenstein W, Offit P, Edwards KM, Plotkin S, eds. Plotkin's Vaccines. (Eighth edition). Philadelphia: Elsevier, 2023;664–89.e12. doi: https://doi.org/10.1016/B978-0-323-79058-1.00039-6.
Stephens DS, Granoff DM, Pollard AJ, Harrison LH. Chapter 40 – Meningococcal Vaccines Directed at Capsular Group B. In Orenstein W, Offit P, Edwards KM, Plotkin S, eds. Plotkin's Vaccines. (Eighth edition). Philadelphia: Elsevier, 2023;690–710.e7. doi: https://doi.org/10.1016/B978-0-323-79058-1.00040-2.
Bertrand-Gerentes I, Fanchon L, Coste F, Glover RE, Guiddir T, Taha MK. Range of clinical manifestations caused by invasive meningococcal disease due to serogroup W: a systematic review. Infect Dis Ther. 2023;12(10):2337–51. doi: https://doi.org/10.1007/s40121-023-00869-z.
Sudbury EL, O'Sullivan S, Lister D, Varghese D, Satharasinghe K. Case manifestations and public health response for outbreak of meningococcal W disease, Central Australia, 2017. Emerg Infect Dis. 2020;26(7):1355–63. doi: https://doi.org/10.3201/eid2607.181941.
Wang B, Santoreneos R, Giles L, Haji Ali Afzali H, Marshall H. Case fatality rates of invasive meningococcal disease by serogroup and age: a systematic review and meta-analysis. Vaccine. 2019;37(21):2768–82. doi: https://doi.org/10.1016/j.vaccine.2019.04.020.
Wang B, Clarke M, Thomas N, Howell S, Afzani HHA, Marshall H. The clinical burden and predictors of sequelae following invasive meningococcal disease in Australian children. Pediatr Infect Dis J. 2014;33(3):316–8. doi: https://doi.org/10.1097/INF.0000000000000043.
Viner RM, Booy R, Johnson H, Edmunds WJ, Hudson L, Bedford H et al. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol. 2012;11(9):774–83. doi: https://doi.org/10.1016/S1474-4422(12)70180-1.
Strifler L, Morris SK, Dang V, Tu HAT, Minhas RS, Jamieson FB et al. The health burden of invasive meningococcal disease: a systematic review. J Pediatric Infect Dis Soc. 2015;5(4):417–30. doi: https://doi.org/10.1093/jpids/piv065.
Deng L, Barton B, Lorenzo J, Rashid H, Dastouri F, Booy R. Longer term outcomes following serogroup B invasive meningococcal disease. J Paediatr Child Health. 2021;57(6):894–902. doi: https://doi.org/10.1111/jpc.15350.
McMillan M, McDonough J, Angliss M, Buttery J, Saunders L, Mathew SM et al. Exploring the health-related quality of life and the lived experience of adolescents following invasive meningococcal disease. Healthcare (Basel). 2024;12(11):1075. doi: https://doi.org/10.3390/healthcare12111075.
Hart J, Dowse GK, Porter M, Speers DJ, Keil AD, Bew JD et al. Obstetric and neonatal invasive meningococcal disease caused by Neisseria meningitidis serogroup W, Western Australia, Australia. Emerg Infect Dis. 2024;30(2):368–71. doi: https://doi.org/10.3201/eid3002.230639.
Birrell MT, Strachan J, Holmes NE, Stevens K, Howden BP, Franklin LJ et al. Clinical manifestations of invasive meningococcal disease in Victoria with the emergence of serogroup W and serogroup Y Neisseria meningitidis. Intern Med J. 2021;51(3):390–7. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/imj.14771. doi: https://doi.org/10.1111/imj.14771.
NCIRS. Significant events in meningococcal vaccination practice in Australia. Sydney: Sydney Children’s Hospitals Network; July 2020. [Accessed on 2 July 2026.]
Ewe K, Fathima P, Effler P, Giele C, Richmond P. Impact of meningococcal ACWY vaccination program during 2017–18 epidemic, Western Australia, Australia. Emerg Infect Dis. 2024;30(2):270–8. doi: https://doi.org/10.3201/eid3002.230144.
Alderson MR, Arkwright PD, Bai X, Black S, Borrow R, Caugant DA et al. Surveillance and control of meningococcal disease in the COVID-19 era: a Global Meningococcal Initiative review. J Infect. 2022;84(3):289–96. doi: https://doi.org/10.1016/j.jinf.2021.11.016.
Brueggemann AB, Jansen van Rensburg MJ, Shaw D, McCarthy ND, Jolley KA, Maiden MCJ et al. Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data. Lancet Digit Health. 2021;3(6):e360–70. doi: https://doi.org/10.1016/S2589-7500(21)00077-7.
Stein-Zamir C, Shoob H, Abramson N, Valinsky L, Jaffe J, Maimoun D et al. Invasive disease due to Neisseria meningitidis: surveillance and trends in Israel prior to and during the COVID-19 pandemic. Microorganisms. 2023;11(9):2212. doi: https://doi.org/10.3390/microorganisms11092212.
Steens A, Knol MJ, Freudenburg-de Graaf W, de Melker HE, van der Ende A, van Sorge NM. Pathogen- and type-specific changes in invasive bacterial disease epidemiology during the first year of the COVID-19 pandemic in the Netherlands. Microorganisms. 2022;10(5):972. doi: https://doi.org/10.3390/microorganisms10050972.
Robert George C, Booy R, Nissen MD, Lahra MM. The decline of invasive meningococcal disease and influenza in the time of COVID-19: the silver linings of the pandemic playbook. Med J Aust. 2022;216(10):504–7. doi: https://doi.org/10.5694/mja2.51463.
Salomon A, Berry I, Tuite AR, Drews S, Hatchette T, Jamieson F et al. Influenza increases invasive meningococcal disease risk in temperate countries. Clin Microbiol Infect. 2020;26(9):1257.e1–7. doi: https://doi.org/10.1016/j.cmi.2020.01.004.
Clark SA, Campbell H, Ribeiro S, Bertran M, Walsh L, Walker A et al. Epidemiological and strain characteristics of invasive meningococcal disease prior to, during and after COVID-19 pandemic restrictions in England. J Infect. 2023;87(5):385–91. doi: https://doi.org/10.1016/j.jinf.2023.09.002.
Taha S, Hong E, Denizon M, Falguières M, Terrade A, Deghmane AE et al. The rapid rebound of invasive meningococcal disease in France at the end of 2022. J Infect Public Health. 2023;16(12):1954–60. doi: https://doi.org/10.1016/j.jiph.2023.10.001.
Taha MK, Martinon-Torres F, Köllges R, Bonanni P, Safadi MAP, Booy R et al. Equity in vaccination policies to overcome social deprivation as a risk factor for invasive meningococcal disease. Expert Rev Vaccines. 2022;21(5):659–74. doi: https://doi.org/10.1080/14760584.2022.2052048.
Geno KA, Gilbert GL, Song JY, Skovsted IC, Klugman KP, Jones C et al. Pneumococcal capsules and their types: past, present, and future. Clin Microbiol Rev. 2015;28(3):871–99. doi: https://doi.org/10.1128/CMR.00024-15.
O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374(9693):893–902. doi: https://doi.org/10.1016/S0140-6736(09)61204-6.
Klugman KP, Malley R, Whitney CG. Chapter 47 – Pneumococcal Conjugate Vaccine and Pneumococcal Common Protein Vaccines. In Orenstein W, Offit P, Edwards KM, Plotkin S, eds. Plotkin's Vaccines. (Eighth edition). Philadelphia: Elsevier, 2023;826–68.e18. doi: https://doi.org/10.1016/B978-0-323-79058-1.00047-5.
Phuong LK, Cheung A, Templeton T, Abebe T, Ademi Z, Buttery J et al. Epidemiology of childhood invasive pneumococcal disease in Australia: a prospective cohort study. Arch Dis Child. 2024;110(1):52–8. doi: https://doi.org/10.1136/archdischild-2024-327497.
Dagan R, van der Beek BA, Ben-Shimol S, Greenberg D, Shemer-Avni Y, Weinberger DM et al. The COVID-19 pandemic as an opportunity for unravelling the causative association between respiratory viruses and pneumococcus-associated disease in young children: a prospective study. EBioMedicine. 2023;90:104493. doi: https://doi.org/10.1016/j.ebiom.2023.104493.
Rybak A, Levy C, Angoulvant F, Auvrignon A, Gembara P, Danis K et al. Association of nonpharmaceutical interventions during the COVID-19 pandemic with invasive pneumococcal disease, pneumococcal carriage, and respiratory viral infections among children in France. JAMA Netw Open. 2022;5(6):e2218959. doi: https://doi.org/10.1001/jamanetworkopen.2022.18959.
Williams PCM, Howard-Jones A, Butters C, Koirala A, Britton PN, Duguid R et al. Clinical and epidemiologic profile of invasive pneumococcal disease in Australian children following the relaxation of nonpharmaceutical interventions against SARS-CoV-2. Pediatr Infect Dis J. 2023;42(9):e341–2. doi: https://doi.org/10.1097/INF.0000000000003972.
Homaira N, Strachan R, Quinn H, Beggs S, Bhuiyan M, Bowen A et al. Real world impact of 13vPCV in preventing invasive pneumococcal pneumonia in Australian children: a national study. Vaccine. 2023;41(1):85–91. doi: https://doi.org/10.1016/j.vaccine.2022.11.006.
Izurieta P, Bahety P, Adegbola R, Clarke C, Hoet B. Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution. Expert Rev Vaccines. 2018;17(6):479–93. doi: https://doi.org/10.1080/14760584.2018.1413354.
Mungall BA, Hoet B, Nieto Guevara J, Soumahoro L. A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children. Expert Rev Vaccines. 2022;21(2):201–14. doi: https://doi.org/10.1080/14760584.2022.2012455.
Grant LR, Slack MPE, Theilacker C, Vojicic J, Dion S, Reinert RR et al. Distribution of serotypes causing invasive pneumococcal disease in older adults from high-income countries and impact of pediatric and adult vaccination policies. Vaccine. 2023;41(38):5662–9. doi: https://doi.org/10.1016/j.vaccine.2023.08.001.
Binte Hossain F, Muscatello D, Jayasinghe S, Jonnagaddala J, Liu B. Uptake of pneumococcal vaccines in older Australian adults before and after universal public funding of PCV13. Vaccine. 2024;42(12):3084–90. doi: https://doi.org/10.1016/j.vaccine.2024.04.012.
Nakashima K, Fukushima W. Strategies for pneumococcal vaccination in older adults in the coming era. Hum Vaccin Immunother. 2024;20(1):2328963. doi: https://doi.org/10.1080/21645515.2024.2328963.
Hjuler T, Wohlfahrt J, Simonsen J, Kaltoft MS, Koch A, Kamper-Jørgensen M et al. Perinatal and crowding-related risk factors for invasive pneumococcal disease in infants and young children: a population-based case-control study. Clin Infect Dis. 2007;44(8):1051–6. doi: https://doi.org/10.1086/512814.
Schoenmakers MC.J, Hament JM, Fleer A, Aerts PC, van Dijk H, Kimpen JLL et al. Risk factors for invasive pneumococcal disease. Rev Medical Microbiol. 2002;13(1):29–36.
Berry I, Tuite AR, Salomon A, Drews S, Harris AD, Hatchette T et al. Association of influenza activity and environmental conditions with the risk of invasive pneumococcal disease. JAMA Netw Open. 2020;3(7):e2010167. doi: https://doi.org/10.1001/jamanetworkopen.2020.10167.
Halstead SB, Hills SL, Marfin AA, Solomon T. Chapter 35 – Japanese Encephalitis Vaccines. In Orenstein W, Offit P, Edwards KM, Plotkin S, eds. Plotkin's Vaccines. (Eighth edition). Philadelphia: Elsevier, 2023;577–607.e11. doi: https://doi.org/10.1016/B978-0-323-79058-1.00035-9.
Impoinvil DE, Baylis M, Solomon T. Japanese encephalitis: on the One Health agenda. Curr Top Microbiol Immunol. 2013;365:205–47. doi: https://doi.org/10.1007/82_2012_243.
Campbell GL, Hills SL, Fischer M, Jacobson JA, Hoke CH, Hombach JM et al. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ. 2011;89(10):766–74, 74A–74E. doi: https://doi.org/10.2471/BLT.10.085233.
Mackenzie JS, Williams DT, van den Hurk AF, Smith DW, Currie BJ. Japanese encephalitis virus: the emergence of genotype IV in Australia and its potential endemicity. Viruses. 2022;14(11):2480. doi: https://doi.org/10.3390/v14112480.
McGuinness SL, Lau CL, Leder K. The evolving Japanese encephalitis situation in Australia and implications for travel medicine. J Travel Med. 2023;30(2):taad029. doi: https://doi.org/10.1093/jtm/taad029.
Waller C, Tiemensma M, Currie BJ, Williams DT, Baird RW, Krause VL. Japanese encephalitis in Australia – a sentinel case. N Engl J Med. 2022;387(7):661–2. doi: https://doi.org/10.1056/NEJMc2207004.
Australian Government Department of Health, Disability and Ageing. Japanese encephalitis virus situation declared a Communicable Disease Incident of National Significance. [Media release.] Canberra: Australian Government Department of Health, Disability and Ageing; 4 March 2022. [Accessed on 5 December 2024.] Available from: https://www.health.gov.au/news/japanese-encephalitis-virus-situation-declared-a-communicable-disease-incident-of-national-significance.
Chen WR, Rico-Hesse R, Tesh RB. A new genotype of Japanese encephalitis virus from Indonesia. Am J Trop Med Hyg. 1992;47(1):61–9. doi: https://doi.org/10.4269/ajtmh.1992.47.61.
Schuh AJ, Guzman H, Tesh RB, Barrett AD. Genetic diversity of Japanese encephalitis virus isolates obtained from the Indonesian archipelago between 1974 and 1987. Vector Borne Zoonotic Dis. 2013;13(7):479–88. doi: https://doi.org/10.1089/vbz.2011.0870.
Baldwin Z, Hueston L, Roberts-Witteveen A, Stanley P, Sheel M, Winkler N et al. The seroprevalence of antibodies to Japanese encephalitis virus in five New South Wales towns at high risk of infection, 2022: a cross-sectional serosurvey. Med J Aust. 2024;220(11):561–5. doi: https://doi.org/10.5694/mja2.52320.
Marsland MJ, Thomson TN, O'Brien HM, Peach E, Bellette J, Humphreys N et al. Serosurvey for Japanese encephalitis virus antibodies following an outbreak in an immunologically naive population, Victoria, 2022: a cross-sectional study. Med J Aust. 2024;220(11):566–72. doi: https://doi.org/10.5694/mja2.52344.
Moss WJ. Measles. Lancet. 2017;390(10111):2490–502. doi: https://doi.org/10.1016/S0140-6736(17)31463-0.
Moss WJ, Strebel PM. Chapter 38 – Measles Vaccines. In Orenstein W, Offit P, Edwards KM, Plotkin S, eds. Plotkin's Vaccines. (Eighth edition). Philadelphia: Elsevier, 2023;629–63.e19. doi: https://doi.org/10.1016/B978-0-323-79058-1.00038-4.
Hübschen JM, Gouandjika-Vasilache I, Dina J. Measles. Lancet. 2022;399(10325):678–90. doi: https://doi.org/10.1016/S0140-6736(21)02004-3.
Gidding HF, Martin NV, Stambos V, Tran T, Dey A, Dowse GK et al. Verification of measles elimination in Australia: application of World Health Organization regional guidelines. J Epidemiol Glob Health. 2016;6(3):197–209. doi: https://doi.org/10.1016/j.jegh.2015.12.004.
Auckland Regional Public Health Service (ARPHS). Measles outbreak in Auckland. [Webpage.] Auckland: ARPHS; 2019. [Accessed on 9 September 2024.] Available from: https://www.arphs.health.nz/health-professional-advice-and-alerts/measles-outbreak-in-auckland-34-cases-at-1-may/.
Alexander KE, Wickens M, Fletcher-Lartey SM. Measles elimination in Australia: hard won, easily lost. Aust J Gen Pract. 2020;49(3):112–4. doi: https://doi.org/10.31128/AJGP-11-19-5147.
Craig AT, Heywood AE, Worth H. Measles epidemic in Samoa and other Pacific islands. Lancet Infect Dis. 2020;20(3):273–5. doi: https://doi.org/10.1016/S1473-3099(20)30053-0.
Williamson KM, Merritt T, Durrheim DN. Australia: an island in a sea of measles. Med J Aust. 2020;213(3):101–3.e1. doi: https://doi.org/10.5694/mja2.50650.
Durrheim DN, Andrus JK, Tabassum S, Bashour H, Githanga D, Pfaff G. A dangerous measles future looms beyond the COVID-19 pandemic. Nat Med. 2021;27(3):360–1. doi: https://doi.org/10.1038/s41591-021-01237-5.
Torjesen I. Measles outbreaks likely as covid pandemic leaves millions of world's children unvaccinated, WHO warns. BMJ. 2021;375:n2755. doi: https://doi.org/10.1136/bmj.n2755.
Minta AA, Ferrari M, Antoni S, Portnoy S, Sbarra A, Lambert B et al. Progress toward measles eimination – worldwide, 2000–2022. MMWR Morb Mortal Wkly Rep. 2023;72(46):1262–8. doi: https://doi.org/10.15585/mmwr.mm7246a3.
Hviid A, Rubin S, Mühlemann K. Mumps. Lancet. 2008;371(9616):932–44. doi: https://doi.org/10.1016/S0140-6736(08)60419-5.
Rubin SA. Chapter 41 – Mumps Vaccines. In Orenstein W, Offit P, Edwards KM, Plotkin S, eds. Plotkin's Vaccines. (Eighth edition). Philadelphia: Elsevier, 2023;663–88.e11. doi: https://doi.org/10.1016/B978-0-323-79058-1.00041-4.
Storen R, Corrigan N. COVID-19: a chronology of state and territory government announcements (up until 30 June 2020). Canberra: Parliament of Australia, Department of Parliamentary Services; 22 October 2020. [Accessed on 19 June 2024.] Available from: https://www.aph.gov.au/About_Parliament/Parliamentary_departments/Parliamentary_Library/Research/Chronologies/2020-21/COVID-19StateTerritoryGovernmentAnnouncements.
Di Pietrantonj C, Rivetti A, Marchione P, Debalini MG, Demicheli V. Vaccines for measles, mumps, rubella, and varicella in children. Cochrane Database Syst Rev. 2021;11(11):CD004407. doi: https://doi.org/10.1002/14651858.CD004407.pub5.
Eriksen J, Davidkin I, Kafatos G, Andrews N, Barbara C, Cohen D et al. Seroepidemiology of mumps in Europe (1996–2008): why do outbreaks occur in highly vaccinated populations? Epidemiol Infect. 2013;141(3):651–66. doi: https://doi.org/10.1017/S0950268812001136.
McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(RR-04):1–34. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6204a1.htm.
Gokhale DV, Brett TS, He B, King AA, Rohani P. Disentangling the causes of mumps reemergence in the United States. Proc Natl Acad Sci U S A. 2023;120(3):e2207595120. doi: https://doi.org/10.1073/pnas.2207595120.
Rubin SA, Link MA, Sauder CJ, Zhang C, Ngo L, Rima BK et al. Recent mumps outbreaks in vaccinated populations: no evidence of immune escape. J Virol. 2012;86(1):615–20. doi: https://doi.org/10.1128/JVI.06125-11.
Cardemil CV, Dahl RM, James L, Wannemuehler K, Gary HE, Shah M et al. Effectiveness of a third dose of MMR vaccine for mumps outbreak control. N Engl J Med. 2017;377(10):947–56. doi: https://doi.org/10.1056/NEJMoa1703309.
Guo A, Leung J, Ayers T, Fields VS, Safi H, Waters C et al. Mumps vaccine effectiveness of a 3rd dose of measles, mumps, rubella vaccine in school settings during a mumps outbreak—Arkansas, 2016–2017. Public Health Pract (Oxf). 2023;6:100404. doi: https://doi.org/10.1016/j.puhip.2023.100404.
Walker J, Adegbija O, Smoll N, Khan A, Whicker J, Carroll H et al. Epidemiology of mumps outbreaks and the impact of an additional dose of MMR vaccine for outbreak control in regional Queensland, Australia, 2017–2018. Commun Dis Intell (2018). 2021;45. doi: https://doi.org/10.33321/cdi.2021.45.67.
Edwards KM, Decker MD. Chapter 44 – Pertussis Vaccines. In Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. Plotkin's Vaccines. (Seventh edition.) Amsterdam: Elsevier, 2018;711–61.e16. doi: https://doi.org/10.1016/B978-0-323-35761-6.00043-2.
Heininger U, Klich K, Stehr K, Cherry JD. Clinical findings in Bordetella pertussis infections: results of a prospective multicenter surveillance study. Pediatrics. 1997;100(6):e10. doi: https://doi.org/10.1542/peds.100.6.e10.
Havers FP, Moro PL, Hariri S, Skoff T. Pertussis. In Hall E, Wodi AP, Hamborsky J, Morelli V, Schillie S, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases (the ‘Pink Book’) (14th edition). Washington DC: United States Centers for Disease Control and Prevention, Public Health Foundation, 2021.
Postels-Multani S, Schmitt HJ, Wirsing von König CH, Bock HL, Bogaerts H. Symptoms and complications of pertussis in adults. Infection. 1995;23(3):139–42. doi: https://doi.org/10.1007/BF01793853.
van der Kooi S, Beard F, Dey A, McIntyre P, Imai C, Amin J. Pertussis notifications decline in Australia during COVID-19 non-pharmaceutical interventions, 2020–2021. Commun Dis Intell (2018). 2024;48. doi: https://doi.org/10.33321/cdi.2024.48.24.
Marshall KS, Quinn HE, Pillsbury AJ, Maguire JE, Lucas RM, Dey A et al. Australian vaccine preventable disease epidemiological review series: pertussis, 2013–2018. Commun Dis Intell (2018). 2022;46. doi: https://doi.org/10.33321/cdi.2022.46.3.
NCIRS. Significant events in diphtheria, tetanus and pertussis vaccination practice in Australia. Sydney: Sydney Children’s Hospitals Network; April 2024. [Accessed on 20 June 2024.]
European Centre for Disease Prevention and Control (ECDC). Rapid risk assessment: Increase of pertussis cases in the EU/EEA: 8 May 2024. Stockholm: ECDC; 8 May 2024. [Accessed on 20 June 2024.]
Smout E, Mellon D, Rae M. Whooping cough rises sharply in UK and Europe. BMJ. 2024;385:q736. doi: https://doi.org/10.1136/bmj.q736.
McHugh L, D'Antoine HA, Sarna M, Binks MJ, Moore HC, Andrews RM et al. The effectiveness of maternal pertussis vaccination for protecting Aboriginal and Torres Strait Islander infants against infection, 2012–2017: a retrospective cohort study. Med J Aust. 2024;220(4):196–201. doi: https://doi.org/10.5694/mja2.52220.
McHugh L, Regan AK, Sarna M, Moore HC, Van Buynder P, Pereira G et al. Inequity of antenatal influenza and pertussis vaccine coverage in Australia: the Links2HealthierBubs record linkage cohort study, 2012–2017. BMC Pregnancy Childbirth. 2023;23(1):314. doi: https://doi.org/10.1186/s12884-023-05574-w.
Regan AK, Moore HC, Binks MJ, McHugh L, Blyth CC, Pereira G et al. Maternal pertussis vaccination, infant immunization, and risk of pertussis. Pediatrics. 2023;152(5):e2023062664. doi: https://doi.org/10.1542/peds.2023-062664.
Quinn HE, Comeau JL, Marshall HS, Elliott EJ, Crawford NW, Blyth CC et al. Pertussis disease and antenatal vaccine effectiveness in Australian children. Pediatr Infect Dis J. 2022;41(3):180–5. doi: https://doi.org/10.1097/INF.0000000000003367.
Jayasundara D, Randall D, Sheridan S, Sheppeard V, Liu B, Richmond PC et al. Estimating the excess burden of pertussis disease in Australia within the first year of life, that might have been prevented through timely vaccination. Int J Epidemiol. 2023;52(1):250–9. doi: https://doi.org/10.1093/ije/dyac175.
Staff M, Nyinawingeri A, Denniss K, Ingleton A, Jeffs J, Corben P. Pertussis morbidity in children 12–59 months of age: a NSW Public Health Network study. Pediatr Infect Dis J. 2019;38(6):553–8. doi: https://doi.org/10.1097/INF.0000000000002234.
Pearce R, Chen J, Chin KL, Guignard A, Latorre LA, MacIntyre CR et al. Population-based study of pertussis incidence and risk factors among persons > 50 Years of age, Australia. Emerg Infect Dis. 2024;30(1):105–15. doi: https://doi.org/10.3201/eid3001.230261.
Hoe Nam L, Chiu CH, Heo JY, Ip M, Jung KS, Menzies R et al. The need for pertussis vaccination among older adults and high-risk groups: a perspective from advanced economies of the Asia Pacific region. Expert Rev Vaccines. 2021;20(12):1603–17. doi: https://doi.org/10.1080/14760584.2021.1990759.
Leong RNF, Wood JG, Liu B, McIntyre PB, Newall AT. High healthcare resource utilisation due to pertussis in Australian adults aged 65 years and over. Vaccine. 2020;38(19):3553–9. doi: https://doi.org/10.1016/j.vaccine.2020.03.021.
Estivariz CF, Burns CC, Macklin GR. Chapter 50 – Poliovirus Vaccine – Live. In Orenstein W, Offit P, Edwards KM, Plotkin S, eds. Plotkin's Vaccines. (Eighth edition). Philadelphia: Elsevier, 2023;914–68.e17. doi: https://doi.org/10.1016/B978-0-323-79058-1.00050-5.
Estivariz CF, Link-Gelles R, Shimabukuro T. Poliomyelitis. In Hall E, Wodi AP, Hamborsky J, Morelli V, Schillie S, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases (the ‘Pink Book’) (14th edition). Washington DC: United States Centers for Disease Control and Prevention, Public Health Foundation, 2021.
World Health Organization (WHO). Polio vaccines: WHO position paper – June 2022. Wkly Epidemiol Rec. 2022;97(25):277–300. Geneva: WHO; 24 June 2022. Available from: https://www.who.int/publications/i/item/WHO-WER9725-277-300.
Adams T. Farewell to polio in the Western Pacific. Bull World Health Organ. 2000;78(12):1375. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC2560664/.
D'Souza RM, Kennett M, Watson C. Australia declared polio free. Commun Dis Intell Q Rep. 2002;26(2):253–60. doi: https://doi.org/10.33321/cdi.2002.26.22.
Global Polio Eradication Initiative. Surveillance Indicators. [Webpage.] Geneva: WHO; 1 May 2024. [Accessed on 30 May 2024.] Available from: https://polioeradication.org/what-we-do/surveillance-indicators/.
Teutsch SM, Nunez CA, Morris A, Eslick GD, Berkhout A, Novakovic D et al. Australian Paediatric Surveillance Unit (APSU) annual surveillance report 2021. Commun Dis Intell (2018). 2022;46. doi: https://doi.org/10.33321/cdi.2022.46.66.
Teutsch SM, Nunez CA, Morris A, Eslick GD, Elliott EJ. Australian Paediatric Surveillance Unit (APSU) annual surveillance report 2022. Commun Dis Intell (2018). 2023;47. doi: https://doi.org/10.33321/cdi.2023.47.46.
Teutsch SM, Nunez CA, Morris A, Eslick GD, Khandaker G, Berkhout A et al. Australian Paediatric Surveillance Unit (APSU) annual surveillance report 2020. Commun Dis Intell (2018). 2021;45. doi: https://doi.org/10.33321/cdi.2021.45.59.
Teutsch SM, Nunez CA, Morris A, McGregor S, King J, Brotherton JM et al. Australian Paediatric Surveillance Unit (APSU) annual surveillance report 2019. Commun Dis Intell (2018). 2020;44. doi: https://doi.org/10.33321/cdi.2020.44.60.
Kaye M, Hobday L, Ibrahim A, Bruggink L, Thorley B. Australian National Enterovirus Reference Laboratory annual report, 2022. Commun Dis Intell (2018). 2023;47. doi: https://doi.org/10.33321/cdi.2023.47.35.
Global Polio Eradication Initiative. Who We Are. [Webpage.] Geneva: WHO. [Accessed on 29 August 2024.] Available from: https://polioeradication.org/who-we-are/.
Global Polio Eradication Initiative. The Virus. [Webpage.] Geneva: WHO; 7 October 2016. [Accessed on 3 June 2024.] Available from: https://polioeradication.org/polio-today/polio-prevention/the-virus/.
Global Polio Eradication Initiative. Global Wild Poliovirus 2018–2024. Geneva: WHO; 22 May 2024. [Accessed on 3 June 2024.] Available from: https://polioeradication.org/wp-content/uploads/2024/05/weekly-polio-analyses-WPV-20240521.pdf.
Hill M, Bandyopadhyay AS, Pollard AJ. Emergence of vaccine-derived poliovirus in high-income settings in the absence of oral polio vaccine use. Lancet. 2022;400(10354):713–5. doi: https://doi.org/10.1016/S0140-6736(22)01582-3.
New York State Department of Health. New York State Department of Health and Rockland County Department of Health Alert the Public to A Case of Polio In the County. [Press release.] Albany (NY): New York State Department of Health; 21 July 2022. Available from: https://health.ny.gov/press/releases/2022/2022-07-21_polio_rockland_county.htm.
WHO. Detection of circulating vaccine derived polio virus 2 (cVDPV2) in environmental samples– the United Kingdom of Great Britain and Northern Ireland and the United States of America. [Online news item.] Geneva: WHO; 14 September 2022. Available from: https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON408.
Bauri M, Wilkinson AL, Ropa B, Feldon K, Snider CJ, Anand A et al. Notes from the field: circulating vaccine-derived poliovirus type 1 and outbreak response – Papua New Guinea, 2018. MMWR Morb Mortal Wkly Rep. 2019;68(5):119–20. doi: https://doi.org/10.15585/mmwr.mm6805a6.
Parker NR, Barralet JH, Bell AM. Q fever. Lancet. 2006;367(9511):679–88. doi: https://doi.org/10.1016/S0140-6736(06)68266-4.
Million M, Raoult D. Recent advances in the study of Q fever epidemiology, diagnosis and management. J Infect. 2015;71(Suppl 1):S2–9. doi: https://doi.org/10.1016/j.jinf.2015.04.024.
Gidding HF, Peng CQ, Graves S, Massey PD, Nguyen C, Stenos J et al. Q fever seroprevalence in Australia suggests one in twenty people have been exposed. Epidemiol Infect. 2020;148:e18. doi: https://doi.org/10.1017/S0950268820000084.
Tozer SJ, Lambert SB, Strong CL, Field HE, Sloots TP, Nissen MD. Potential animal and environmental sources of Q fever infection for humans in Queensland. Zoonoses Public Health. 2014;61(2):105–12. doi: https://doi.org/10.1111/zph.12051.
Tissot-Dupont H, Amadei MA, Nezri M, Raoult D. Wind in November, Q fever in December. Emerg Infect Dis. 2004;10(7):1264–9. doi: https://doi.org/10.3201/eid1007.030724.
Tan T, Heller J, Firestone S, Stevenson M, Wiethoelter A. A systematic review of global Q fever outbreaks. One Health. 2024;18:100667. doi: https://doi.org/10.1016/j.onehlt.2023.100667.
Roughan M, Hodge E, Khan A, Chor J. Evolving epidemiology of Q fever in Wide Bay. Commun Dis Intell (2018). 2023;47. doi: https://doi.org/10.33321/cdi.2023.47.36.
Gidding HF, Faddy HM, Durrheim DN, Graves SR, Nguyen C, Hutchinson P et al. Seroprevalence of Q fever among metropolitan and non-metropolitan blood donors in New South Wales and Queensland, 2014–2015. Med J Aust. 2019;210(7):309–15. doi: https://doi.org/10.5694/mja2.13004.
Tozer SJ, Lambert SB, Sloots TP, Nissen MD. Q fever seroprevalence in metropolitan samples is similar to rural/remote samples in Queensland, Australia. Eur J Clin Microbiol Infect Dis. 2011;30(10):1287–93. doi: https://doi.org/10.1007/s10096-011-1225-y.
Hutchinson P, Ostini R. Southern Queensland general practitioners' knowledge and attitudes towards Q fever and behaviours in the management of the disease. Aust J Gen Pract. 2024;53(5):321–5. doi: https://doi.org/10.31128/AJGP-10-22-6598.
Mathews KO, Norris JM, Phalen D, Malikides N, Savage C, Sheehy PA et al. Factors associated with Q fever vaccination in Australian wildlife rehabilitators. Vaccine. 2023;41(1):201–10. doi: https://doi.org/10.1016/j.vaccine.2022.10.082.
Gunther MJ, Heller J, Hayes L, Hernandez-Jover M. Dairy goat producers' understanding, knowledge and attitudes towards biosecurity and Q-fever in Australia. Prev Vet Med. 2019;170:104742. doi: https://doi.org/10.1016/j.prevetmed.2019.104742.
Sellens E, Norris JM, Dhand NK, Heller J, Hayes L, Gidding HF et al. Q fever knowledge, attitudes and vaccination status of Australia's veterinary workforce in 2014. PLoS One. 2016;11(1):e0146819. doi: https://doi.org/10.1371/journal.pone.0146819.
Gidding HF, Wallace C, Lawrence GL, McIntyre PB. Australia's national Q fever vaccination program. Vaccine. 2009;27(14):2037–41. doi: https://doi.org/10.1016/j.vaccine.2009.02.007.
Rahaman MR, Marshall H, Milazzo A, Crabb D, Bi P. Q fever prevention and vaccination: Australian livestock farmers' knowledge and attitudes to inform a One Health approach. One Health. 2021;12:100232. doi: https://doi.org/10.1016/j.onehlt.2021.100232.
Crawford SE, Ramani S, Tate JE, Parashar UD, Svensson L, Hagbom M et al. Rotavirus infection. Nat Rev Dis Primers. 2017;3:17083. doi: https://doi.org/10.1038/nrdp.2017.83.
Tate JE, Cortese MM, Offit PA, Parashar UD. Chapter 53 – Rotavirus Vaccines. In Orenstein W, Offit P, Edwards KM, Plotkin S, eds. Plotkin's Vaccines. (Eighth edition). Philadelphia: Elsevier, 2023;1005–24.e11. doi: https://doi.org/10.1016/B978-0-323-79058-1.00053-0.
Gurwith M, Wenman W, Hinde D, Feltham S, Greenberg H. A prospective study of rotavirus infection in infants and young children. J Infect Dis. 1981;144(3):218–24. doi: https://doi.org/10.1093/infdis/144.3.218.
Buttery JP, Lambert SB, Grimwood K, Nissen MD, Field EJ, Macartney KK et al. Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia's National Childhood vaccine schedule. Pediatr Infect Dis J. 2011;30(1 Suppl):S25–9. doi: https://doi.org/10.1097/INF.0b013e3181fefdee.
Dey A, Wang H, Menzies R, Macartney K. Changes in hospitalisations for acute gastroenteritis in Australia after the national rotavirus vaccination program. Med J Aust. 2012;197(8):453–7. doi: https://doi.org/10.5694/mja12.10062.
Macartney KK, Porwal M, Dalton D, Cripps T, Maldigri T, Isaacs D et al. Decline in rotavirus hospitalisations following introduction of Australia's national rotavirus immunisation programme. J Paediatr Child Health. 2011;47(5):266–70. doi: https://doi.org/10.1111/j.1440-1754.2010.01953.x.
Middleton BF, Danchin M, Fathima P, Bines JE, Macartney K, Snelling TL. Review of the health impact of the oral rotavirus vaccine program in children under 5 years in Australia: 2006–2021. Vaccine. 2023;41(3):636–48. doi: https://doi.org/10.1016/j.vaccine.2022.12.008.
Ward K, Dey A, Menzies R, Mahajan D, Hull B, Macartney K et al. Evaluation of the National Rotavirus Immunisation Program. Final report. Sydney: Sydney Children’s Hospitals Network, NCIRS; April 2011. Available from: https://www.ncirs.org.au/sites/default/files/2018-11/NCIRS-Rotavirus-Evaluation-FINAL-REPORT.pdf.
Phua KB, Quak SH, Lee BW, Emmanuel SC, Goh P, Han HH et al. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants. J Infect Dis. 2005;192(Suppl 1):S6–16. doi: https://doi.org/10.1086/431511.
Roczo-Farkas S, Thomas S, Bogdanovic-Sakran N, Donato CM, Lyons EA, Bines J. Australian Rotavirus Surveillance Program: Annual Report, 2021. Commun Dis Intell (2018). 2022;46. doi: https://doi.org/10.33321/cdi.2022.46.75.
Salinas B, Pérez Schael I, Linhares AC, Ruiz Palacios GM, Guerrero ML, Yarzábal JP et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: a randomized, placebo-controlled trial in Latin American infants. Pediatr Infect Dis J. 2005;24(9):807–16. doi: https://doi.org/10.1097/01.inf.0000178294.13954.a1.
Snelling TL, Andrews RM, Kirkwood CD, Culvenor S, Carapetis JR. Case-control evaluation of the effectiveness of the G1P[8] human rotavirus vaccine during an outbreak of rotavirus G2P[4] infection in central Australia. Clin Infect Dis. 2011;52(2):191–9. doi: https://doi.org/10.1093/cid/ciq101.
Middleton BF, Danchin M, Quinn H, Ralph AP, Pingault N, Jones M et al. Retrospective case-control study of 2017 G2P[4] rotavirus epidemic in rural and remote Australia. Pathogens. 2020;9(10):790. doi: https://doi.org/10.3390/pathogens9100790.
Reef SE, Plotkin SA. Chapter 54 – Rubella Vaccines. In Orenstein W, Offit P, Edwards KM, Plotkin S, eds. Plotkin's Vaccines. (Eighth edition). Philadelphia: Elsevier, 2023;1025–56.e19. doi: https://doi.org/10.1016/B978-0-323-79058-1.00054-2.
Thompson KM, Simons EA, Badizadegan K, Reef SE, Cooper LZ. Characterization of the risks of adverse outcomes following rubella infection in pregnancy. Risk Anal. 2016;36(7):1315–31. doi: https://doi.org/10.1111/risa.12264.
Gregg NM. Congenital cataract following German measles in the mother. 1941. Epidemiol Infect. 1991;107(1):iii–xiv. doi: https://doi.org/10.1017/s0950268800048627.
Miller E, Cradock-Watson J, Pollock T. Consequences of confirmed maternal rubella at successive stages of pregnancy. Lancet. 1982;320(8302):781–4. doi: https://doi.org/10.1016/s0140-6736(82)92677-0.
WHO. Singapore wipes out measles; Australia, Brunei Darussalam and Macao SAR (China) eliminate rubella. [Media release.] Geneva: WHO; 31 October 2018. [Accessed on 2 May 2024.] Available from: https://www.who.int/westernpacific/news/item/31-10-2018-singapore-wipes-out-measles-australia-brunei-darussalam-and-macao-sar-(china)-eliminate-rubella.
Hull BP, Beard FH, Hendry AJ, Dey A, Macartney K. ‘No jab, no pay’: catch-up vaccination activity during its first two years. Med J Aust. 2020;213(8):364–9. doi: https://doi.org/10.5694/mja2.50780.
Glynn-Robinson A, Knapp JK, Durrheim DN. How Australia's measles control activities have catalyzed rubella elimination. Int J Infect Dis. 2022;114:72–8. doi: https://doi.org/10.1016/j.ijid.2021.11.003.
Hull B, Hendry A, Dey A, Brotherton J, Macartney K, Beard F et al. Annual Immunisation Coverage Report 2021. Commun Dis Intell (2018). 2023;47. doi: https://doi.org/10.33321/cdi.2023.47.47.
Yen LM, Thwaites CL. Tetanus. Lancet. 2019;393(10181):1657–68. doi: https://doi.org/10.1016/S0140-6736(18)33131-3.
Hassel B. Tetanus: pathophysiology, treatment, and the possibility of using botulinum toxin against tetanus-induced rigidity and spasms. Toxins (Basel). 2013;5(1):73–83. doi: https://doi.org/10.3390/toxins5010073.
Scobie HM, Khetsuriani N, Tohme RA, et al. Chapter 59 – Tetanus Toxoid. In Orenstein W, Offit P, Edwards KM, Plotkin S, eds. Plotkin's Vaccines. (Eighth edition). Philadelphia: Elsevier, 2023;1117–41.e16. doi: https://doi.org/10.1016/B978-0-323-79058-1.00059-1.
Leclair JM, Zaia JA, Levin MJ, Congdon RG, Goldmann DA. Airborne transmission of chickenpox in a hospital. N Engl J Med. 1980;302(8):450–3. doi: https://doi.org/10.1056/NEJM198002213020807.
Nagel MA, Gershon AA, Mahalingam R, Niemeyer CS, Bubak AN. Chapter 63 – Varicella Vaccines. In Orenstein W, Offit P, Edwards KM, Plotkin S, eds. Plotkin's Vaccines. (Eighth edition). Philadelphia: Elsevier, 2023;1215–50.e17. doi: https://doi.org/10.1016/B978-0-323-79058-1.00063-3.
Meyer PA, Seward JF, Jumaan AO, Wharton M. Varicella mortality: trends before vaccine licensure in the United States, 1970–1994. J Infect Dis. 2000;182(2):383–90. doi: https://doi.org/10.1086/315714.
Forrest JM, Mego S, Burgess MA. Congenital and neonatal varicella in Australia. J Paediatr Child Health. 2000;36(2):108–13. doi: https://doi.org/10.1046/j.1440-1754.2000.00474.x.
Quinn HE, Gidding HF, Marshall HS, Booy R, Elliott EJ, Richmond P et al. Varicella vaccine effectiveness over 10 years in Australia; moderate protection from 1-dose program. J Infect. 2019;78(3):220–5. doi: https://doi.org/10.1016/j.jinf.2018.11.009.
Sheridan SL, Quinn HE, Hull BP, Ware RS, Grimwood K, Lambert SB. Impact and effectiveness of childhood varicella vaccine program in Queensland, Australia. Vaccine. 2017;35(27):3490–7. doi: https://doi.org/10.1016/j.vaccine.2017.05.013.
Marin M, Meissner HC, Seward JF. Varicella prevention in the United States: a review of successes and challenges. Pediatrics. 2008;122(3):e744–51. doi: https://doi.org/10.1542/peds.2008-0567.
Seward JF, Marin M, Vázquez M. Varicella vaccine effectiveness in the US vaccination program: a review. J Infect Dis. 2008;197(Suppl 2):S82–9. doi: https://doi.org/10.1086/522145.
Leung J, Lopez AS, Blostein J, Thayer N, Zipprich J, Clayton A et al. Impact of the US two-dose varicella vaccination pProgram on the epidemiology of varicella outbreaks: data from nine states, 2005–2012. Pediatr Infect Dis J. 2015;34(10):1105–9. doi: https://doi.org/10.1097/INF.0000000000000821.
Marin M, Lopez AS, Melgar M, Dooling K, Curns AT, Leung J. Decline in severe varicella disease during the United States varicella vaccination program: hospitalizations and deaths, 1990–2019. J Infect Dis. 2022;226(Suppl 4):S407–15. doi: https://doi.org/10.1093/infdis/jiac242.
Dyda A, Broome A, Rawlinson W, Mahimbo A, Saha A, Kefalas B et al. Measles, mumps, rubella and varicella antibodies among international and domestic university students. J Travel Med. 2024;31(1):taae004. doi: https://doi.org/10.1093/jtm/taae004.
Walker J, Teutsch S, Morris A, Eslick GD, Al Imam MH, Khan A et al. Active prospective national surveillance for congenital and neonatal varicella in Australia shows potential prevention opportunities. Vaccine X. 2023;13:100278. doi: https://doi.org/10.1016/j.jvacx.2023.100278.
Patil A, Goldust M, Wollina U. Herpes zoster: a review of clinical manifestations and management. Viruses. 2022;14(2):192. doi: https://doi.org/10.3390/v14020192.
Levin MJ. Chapter 66 – Zoster Vaccines. In Orenstein W, Offit P, Edwards KM, Plotkin S, eds. Plotkin's Vaccines. (Eighth edition). Philadelphia: Elsevier, 2023;1334–49.e7. doi: https://doi.org/10.1016/B978-0-323-79058-1.00066-9.
Brisson M, Edmunds WJ, Law B, Gay NJ, Walld R, Brownell M et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect. 2001;127(2):305–14. doi: https://doi.org/10.1017/s0950268801005921.
Schmader K. Herpes zoster in older adults. Clin Infect Dis. 2001;32(10):1481–6. doi: https://doi.org/10.1086/320169.
Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis. 2004;4(1):26–33. doi: https://doi.org/10.1016/s1473-3099(03)00857-0.
NCIRS. Significant events in zoster vaccination practice in Australia. Sydney: Sydney Children’s Hospitals Network; March 2025. [Accessed on 2 July 2026.]
Marsland MJ, Glynn-Robinson A, Gang RF, Strachan J. The impact of the National Shingles Vaccination Program on the epidemiology of herpes zoster among adults ≥ 60 years in Victoria, Australia. Commun Dis Intell (2018). 2023;47. doi: https://doi.org/10.33321/cdi.2023.47.56.
Phakey S, Rogers SL, Hall AJ, Lim LL. Reduction in herpes zoster antiviral use since the introduction of the live-attenuated zoster vaccine on Australia's national immunisation program: a population-based study from 1994 to 2019. Infect Dis Ther. 2023;12(2):711–26. doi: https://doi.org/10.1007/s40121-022-00749-y.
Shrestha AC, Field E, Rajmokan M, Lambert SB. Assessing the impact of chickenpox and shingles vaccination using intermittent enhanced surveillance in Queensland, Australia. Vaccine. 2023;41(50):7539–47. doi: https://doi.org/10.1016/j.vaccine.2023.11.015.
Irigoyen-Mansilla VM, Gil-Prieto R, Gea-Izquierdo E, Barrio-Fernández JL, Hernández-Barrera V, Gil-de-Miguel A. Hospitalization burden related to herpes zoster infection during the COVID-19 pandemic in Spain (2020–2021). Hum Vaccin Immunother. 2023;19(2):2256047. doi: https://doi.org/10.1080/21645515.2023.2256047.
Podubinski T, Townsin L, Thompson SC, Tynan A, Argus G. Experience of healthcare access in Australia during the first year of the COVID-19 pandemic. Int J Environ Res Public Health. 2021;18(20):10687. doi: https://doi.org/10.3390/ijerph182010687.
Sheel M, Beard FH, Dey A, Macartney K, McIntyre PB. Rates of hospitalisation for herpes zoster may warrant vaccinating Indigenous Australians under 70. Med J Aust. 2017;207(9):395–6. doi: https://doi.org/10.5694/mja16.01468.
Huang YA, Li-Kim-Moy J, Jayasinghe S, Chiu C, Macartney K, Liu B et al. ATAGI Targeted Review 2022: vaccination for prevention of herpes zoster in Australia. Commun Dis Intell (2018). 2023;47. doi: https://doi.org/10.33321/cdi.2023.47.21.
Public Health Committee, National Health Medical Research Council (NHMRC). Surveillance case definitions: endorsed at the 115th Session of NHMRC, Adelaide, June 1993. Canberra: NHMRC; March 1994.
CDNA Surveillance Case Definitions Woking Group. Notifiable diseases, Australia, 2004. Commun Dis Intell Q Rep. 2004;28(1):1–5. doi: https://doi.org/10.33321/cdi.2004.28.1.
AIHW. Admitted patient care 2021–22: Appendix information. Canberra: Australian Government, AIHW; 2023. Available from: https://www.aihw.gov.au/getmedia/9cfaab58-b491-4b26-803a-7b829997d35b/admitted-patient-care-2021-22-appendices.pdf.
New South Wales State Government (NSW Government). HealthStats NSW: Hospital statistics in NSW. [Webpage.] Sydney: NSW Government; 2024. [Accessed on 17 October 2024.] Available from: https://www.healthstats.nsw.gov.au/page/Hospitalisation-description.
ABS. Feature article: which population to use for age standardisation? [Online document.] Canberra: ABS; 26 September 2013. [Accessed on 4 October 2024.]
Dobson AJ, Kuulasmaa K, Eberle E, Scherer J. Confidence intervals for weighted sums of Poisson parameters. Stat Med. 1991;10(3):457–62. doi: https://doi.org/10.1002/sim.4780100317.
Independent Health and Aged Care Pricing Authority. (IHACPA). How to classify COVID-19: Guidance for data analysts using ICD-10-AM Eleventh Edition. Sydney: IHACPA; 15 December 2022.
AIHW. Admitted patient care 2019-20. 3: Who used these services? [Downloadable resource.] Canberra: Australian Government, AIHW; 14 December 2021. [Accessed on 17 October 2024.] Available from: https://www.aihw.gov.au/reports-data/myhospitals/content/data-downloads.
AIHW. Admitted patient care 2020-21. 3: Who used admitted patient services? [Downloadable resource.] Canberra: Australian Government, AIHW; 1 June 2022. [Accessed on 17 October 2024.] Available from: https://www.aihw.gov.au/reports-data/myhospitals/content/data-downloads.
AIHW. Admitted patient care 2021-22. 3: Who used admitted patient services? [Downloadable resource.] Canberra: Australian Government, AIHW; 31 May 2023. [Accessed on 17 October 2024.] Available from: https://www.aihw.gov.au/reports-data/myhospitals/content/data-downloads.
AIHW. Indigenous identification in hospital separations data; quality report. Canberra: Australian Government, AIHW; 1 May 2013. Available from: https://www.aihw.gov.au/reports/indigenous-australians/indigenous-identification-in-hospital-separations/contents/table-of-contents.
ABS. Causes of Death, Australia methodology. (Reference period: 2022). Deaths of Aboriginal and Torres Strait Islander people. [Webpage.] Canberra: ABS; 27 September 2023. [Accessed on 4 October 2024.] Available from: https://www.abs.gov.au/methodologies/causes-death-australia-methodology/2022#deaths-of-aboriginal-and-torres-strait-islander-people.
NCIRS. History of immunisation in Australia. [Webpage.] Sydney: Sydney Children’s Hospitals Network; 2024. [Accessed on 5 December 2024.] Available from: https://ncirs.org.au/health-professionals/history-immunisation-australia.
Government of South Australia Department of Health (SA Health). Japanese encephalitis virus (JEV) vaccine. [Webpage.] Adelaide: SA Health; 2024. [Accessed on 5 December 2024.] Available from: https://www.sahealth.sa.gov.au/wps/wcm/connect/public+content/sa+health+internet/conditions/infectious+diseases/japanese+encephalitis/access+to+japanese+encephalitis+virus+vaccine.
Government of Western Australia Department of Health (WA Health). Japanese encephalitis. [Webpage.] Perth: WA Health; 25 October 2023. [Accessed on 5 December 2024.] Available from: https://www.healthywa.wa.gov.au/Articles/J_M/Japanese-encephalitis.
Northern Territory Government. Free Japanese encephalitis vaccine. [Webpage.] Darwin: Northern Territory Government; 2024. [Accessed on 5 December 2024.] Available from: https://nt.gov.au/wellbeing/healthy-living/immunisation/free-japanese-encephalitis-vaccine.
NSW Government Department of Health (NSW Health). Japanese encephalitis virus (JEV) vaccination. [Webpage.] Sydney: NSW Health; 2023. [Accessed on 5 December 2024.] Available from: https://www.health.nsw.gov.au/Infectious/jev/Pages/vaccination.aspx.
Queensland State Government. Japanese encephalitis. [Webpage.] Brisbane: Queensland State Government; 2024. [Accessed on 5 December 2024.] Available from: https://www.qld.gov.au/health/condition/infections-and-parasites/viral-infections/japanese-encephalitis.
Tasmania State Government Department of Health (Tasmania Health). Japanese Encephalitis virus (JEV). [Webpage.] Hobart: Tasmania Health; 14 September 2022. [Accessed on 5 December 2024.] Available from: https://www.health.tas.gov.au/publications/japanese-encephalitis-virus.
Victoria State Government Department of Health (Victoria Health). Japanese encephalitis. [Webpage.] Melbourne: Victoria Health; 2024. [Accessed on 5 December 2024.] Available from: https://www.health.vic.gov.au/infectious-diseases/japanese-encephalitis.
NCIRS. Significant events in COVID-19 vaccination practice in Australia. Sydney: Sydney Children’s Hospitals Network; November 2025. [Accessed on 2 July 2026.]
Hall R. Notifiable diseases surveillance, 1917 to 1991. Commun Dis Intell. 1993;17(11):226-236. doi: https://doi.org/10.33321/cdi.1993.17.01.
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2026 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
